PDL’s generic warning

PHARMACEUTICAL Defence Limited (PDL) is warning pharmacists they could face disciplinary action if they make generic substitutions where it has not been authorised.

In a practice alert issued yesterday, PDL noted “some pharmacists feel that they can make generic substitutions where it is unauthorised and that they will act without consequence - this is not the case”.

“Complaints to pharmacy regulators usually happen in one of two ways,” the alert said.

“Consumers who specifically direct that no substitution take place will often file a complaint if a pharmacy generically substitutes without their permission.

“Alternatively, a prescriber who ‘ticks the box’ may report a pharmacist for unauthorised substitution if they become aware that this has occurred.

“Consumers who have their directions on no substitution ignored will often choose to change pharmacies which is an economic it to the business.

“There are often good reasons why substitution of brands should not take place.

“Commonly with elderly patients or those with poor health literacy, swapping away from a familiar brand may lead to confusion and medical misadventure.”

PDL noted there were some drugs, including warfarin that should never have their brands interchanged for clinical reasons of differing bioavailability, while brand consistency should be maintained for anti-epileptics.

PDL also warned having a sign stating that it is the pharmacy’s policy to use generics is not a license to substitute, noting that a consumer must verbally agree that generic substitution is acceptable to them.